Manchester medical device startup with a neurostimulation system to treat swallowing disorders (dysphagia).
| Date | Round | Amount |
|---|---|---|
| Mar 2024 | Series D Plus Phagenesis closed a $42M all-equity Series D led by EQT Life Sciences and co-led by Sectoral to commercialise its FDA-approved dysphagia therapy in the US. | $42M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.